



A Meeting of the **Borders Area Drugs and Therapeutics Committee** held at 12:30pm on
Wednesday, 20th JANUARY 2021 via Microsoft Teams

MINUTE

Present: Alison Wilson (Director of Pharmacy) (Chair) (AW); Keith Maclure (Lead Pharmacist – Medicines Utilization & Planning) (KMacl); Adrian Mackenzie (Lead Pharmacist Community) (AMack); Dr Nicola Henderson (GP) (NHKeith Allan (Public Health Consultant) (KA); Rhona Morrison (Interim Medicines Governance Lead Nurse) (RM); Effie Dearden (DME Consultant); Andrew Leitch (Lay Member) (AL); Kate Warner (Minute Secretary) (KW)

| Item | Situation; Background; Assessment | Recommendation | Lead | Timescale |
|------|--|--|------|-----------------|
| 1. | Apologies and Announcements: Liz Leitch, Formulary Pharmacist;); Cathryn Park (Lead Pharmacist, Acute Care & Medicines Governance) (CP); Dr Ed James (Consultant) (EJ) | | | |
| 2. | Declarations of Interest: None | | | |
| 3. | DRAFT Minute previous meeting | | | |
| 3.1 | Draft minute from 18 th November 2020 meeting was approved as an accurate record of the meeting. | Upload to web | KW | Within 24 hours |
| 4. | Matters Arising | | | |
| 4.1 | Updated - Independent Prescriber / Nurse Formulary policy; approved at last ADTC meeting with changes as attached. Link to intranet to NMPs. | ADTC Noted; upload & send link to NMPs | KW | 25/01/2021 |
| 4.2 | Guanfacine added to formulary as third choice after approval; specialist use only for ADHD; to be added to the existing Shared Care Agreement for ADHD. | ADTC Noted | | |
| 5. | NEW MEDICINE APPLICATIONS: | | | |
| 5.1 | Approved for use by email; application and approval letter attached; see item 8.4 letter – REMAP-CAP trial. | ADTC Noted | | |
| 5.2 | Non formulary request for Levocarbentine was discussed. | Move discussion to NFR folder; letter to applicant | KW | 25/01/2021 |
| 6. | PATIENT & MEDICINES SAFETY: | | | |
| 6.1 | Datix Review – to focus on key incidents/themes November work completed for insulin, antibiotics in December, and anticoagulants in January. February controlled drugs. | ADTC Noted | | |

| | | | | |
|-----------|--|--|----|------------|
| 7. | CLINICAL POLICIES, PROCEDURES and GUIDELINES for APPROVAL: | | | |
| 7.1 | Drug & Therapeutic Industry Engagement Policy – current (attached policy) for update/approval along with the summary of key points. ADTC approved with change to the Pharmacy job title that staff should contact regarding restrictions – change to Senior Pharmacist. All prescribers to be included in notification of the policy when updated on intranet/internet and link to be sent to non-medical prescribers and in pharmacy prescribing bulletin. | ADTC Approved Update and upload Link to NMPs and DMacB for bulletin | KW | 25/01/2021 |
| 7.2 | SOP for prescribing pads distribution has been updated to ensure that accountability and audit of who picks up pads from Pharmacy is covered. | ADTC Approved | | |
| 8. | FOR INFORMATION and NOTING: | | | |
| 8.1 | AW updated ADTC on progress of ward automated cabinets – as soon as ITU and Theatre available to Estates they will do the work to ensure ready for installation of cabinets and will review work required for ward 9, MKU and BSU followed by completion of work required. At this time all cabinets can be rolled out – expected to be April; can be delayed if required. Robotics - pharmacy robotic application has been reviewed by Capital Group and in February the Group will re-review and prioritise depending on other areas required. HEPMA: Health Improvement Scotland have started shared learning sessions; Dr C Kelly attended the first session with second one coming soon after which Dr Kelly and Head of IM&T JS will discuss how this will progress. Next step will be an outline business case to the Board for consideration and sign off. NHS Lothian has rolled out HEPMA to Edinburgh Royal and is in the process of rolling out to Western General; NHS Fife has put out to tender and have a preferred supplier. AW also updated ADTC that Dr Chris Evans is leaving NHS Borders in February and giving up his post as medical prescribing advisor. This post can be split into two (1PA per week flexible) with either one or two consultants able to apply – to be offered to all. Roles will require medical prescribing advisor/attending MRG and other medicines governance committee meetings and support for HEPMA – this is to be discussed with Dr C Kelly, new Clinical CIO/eHealth Lead. Roles can be split to suit. | ADTC Noted | | |
| 8.2 | Therapeutic anticoagulation (Heparin) in the management of severe COVID-19 (SARS-CoV-2 Positive) patients. | ADTC Noted | | |
| 8.3 | Letter – from Chief Pharmaceutical Officer re Astra Zeneca doses per vial sent 8 th January 2021; AW updated ADTC on potential waste in multi-use vials which this letter addresses. 1 extra dose can be taken from Astra Zeneca and Pfizer vials. AMack reported that this has been discussed with primary care and agreed the letter refers to “an additional dose” = 1 dose. 11 doses in total supported with 11 th at discretion. Differences in syringe explained. | ADTC Noted | | |
| 8.4 | Information for issue to relevant healthcare professionals about use of tocilizumab and sarilumab for adult ICU patients with COVID-19 pneumonia. Information circulated nationally. | ADTC Noted | | |
| 8.5 | Lothian Joint Formulary website update is complete with the new platform expanding the traditional formulary structure, based around BNF chapters, by presenting condition-based | ADTC Noted Invite Jane Browning | KW | March |

| | | | | |
|--|---|---|----|------------|
| | medicine recommendations. These place each formulary recommendation in context to illustrate how the medicine is used in the treatment of patients with common conditions. NHS Lothian is the first Health Board to utilise this new platform and the migration of the LJF will be the first step in establishing a new regional formulary for the East of Scotland. AW is meeting with regional Boards next week to review expectations from each Board and how much flexibility will be available to accommodate different Board/patient needs. | and Kirsty MacFarlane, Regional Formulary Team back to ADTC for update. | | meeting |
| 9. | FEEDBACK from SUB GROUPS | | | |
| 9.1 | Borders Formulary Committee DRAFT Minute – meeting held 16 th December 2020 | ADTC Noted | | |
| 9.2 | Antimicrobial Management Team DRAFT Minute – no recent meeting | | | |
| 9.3 | Anticoagulant Committee DRAFT Minute – next meeting 29 th January 2021 | | | |
| 9.4 | IV Therapy Group DRAFT Minute – meeting held 11 November 2020 | ADTC Noted | | |
| 9.5 | Tissue Viability Steering Group – no recent meeting | | | |
| 9.6 | Wound Formulary Group DRAFT Minute – meeting held 25 th November 2020. | ADTC Noted | | |
| 9.7 | NHS Lothian ADTC Minute – meeting held 2 nd October 2020; minute not yet available for meeting held 4 th December 2020 | ADTC Noted | | |
| 10. | AOCB | | | |
| 10.1 | Meeting clashed discussed; ADTC meeting to be changed to fourth Wednesday of the month to remain in line with BFC, MRG and PCPG meetings. | Issue new meeting makers and email | KW | 25/01/2021 |
| Date and time of next meeting: 24th March 2021 at 12:30pm via Microsoft Teams. | | | | |